RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 1, 2013
Released June 2013

Featuring interviews with Drs Charles S Fuchs, Tanios Bakaii-Saab, Emily K Bergsland and Josep Tabernero. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” gastrointestinal (GI) tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.

    LEARNING OBJECTIVES

    • Counsel patients with Stage II colon cancer on appropriate adjuvant therapeutic options based on an evaluation of their individual risk of recurrence estimated from clinical, pathologic and genomic biomarkers.
    • Effectively apply the results of practice-changing clinical research to the selection and sequencing of chemobiologic regimens for patients with metastatic CRC.
    • Evaluate clinical scenarios in which treatment rather than observation is warranted for patients with metastatic neuroendocrine tumors of the GI tract, and identify the optimal sequencing of systemic therapies for these patients.
    • Educate patients with metastatic gastric or pancreatic cancer regarding approved and novel treatment approaches and their associated risks and benefits.
    • Evaluate therapeutic options for patients with imatinib- and sunitinib-resistant GI stromal tumors.
    • Counsel appropriately selected patients with GI cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains an audio component. The participant should review the CME information and listen to the audio MP3s.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FuchsAdvisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi. Dr Bekaii-SaabConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Onyx Pharmaceuticals Inc, Sanofi; Data and Safety Monitoring Board: Polaris Group; Paid Research: Pfizer Inc. Dr BergslandAdvisory Committee: ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company; Paid Research: Novartis Pharmaceuticals Corporation; Research Support: Genentech BioOncology, Sanofi. Dr TaberneroConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi; Honoraria: Amgen Inc, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals and Sanofi.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2013
    Expiration date: June 2014

Acknowledge and close

Listen to audio:
Gastrointestinal Cancer Update, Issue 1, 2013
Released June 2013

Featuring interviews with Drs Charles S Fuchs, Tanios Bakaii-Saab, Emily K Bergsland and Josep Tabernero. (Text and Audio Content)

Read print: